These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 23943214)
1. Response to letter regarding article, "CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China". Zhang M; Xu Y Stroke; 2013 Sep; 44(9):e108. PubMed ID: 23943214 [No Abstract] [Full Text] [Related]
2. Letter by Dong et al regarding article, "CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China". Dong Y; Cheng X; Dong Q Stroke; 2013 Sep; 44(9):e107. PubMed ID: 23943216 [No Abstract] [Full Text] [Related]
3. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828 [TBL] [Abstract][Full Text] [Related]
4. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients. Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336 [TBL] [Abstract][Full Text] [Related]
5. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Chan MY; Tan K; Tan HC; Huan PT; Li B; Phua QH; Lee HK; Lee CH; Low A; Becker RC; Ong WC; Richards MA; Salim A; Tai ES; Koay E Pharmacogenomics; 2012 Apr; 13(5):533-42. PubMed ID: 22462746 [TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091 [TBL] [Abstract][Full Text] [Related]
7. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986 [TBL] [Abstract][Full Text] [Related]
8. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117 [TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Jin B; Ni HC; Shen W; Li J; Shi HM; Li Y Mol Biol Rep; 2011 Mar; 38(3):1697-702. PubMed ID: 20845077 [TBL] [Abstract][Full Text] [Related]
10. Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke. Bennett D; Yan B J Clin Neurosci; 2013 Jun; 20(6):767-70. PubMed ID: 23618682 [TBL] [Abstract][Full Text] [Related]
11. Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Liu Y; Liu N; Li W; Shao H; Zhi H; Li J Pharmacology; 2013; 91(3-4):165-72. PubMed ID: 23429358 [TBL] [Abstract][Full Text] [Related]
12. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151 [TBL] [Abstract][Full Text] [Related]
13. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
14. [Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian]. Fang L; Zhao Y; Wang N; Yang Z; Huang H; Lin M Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):871-6. PubMed ID: 26663068 [TBL] [Abstract][Full Text] [Related]
15. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Mejin M; Tiong WN; Lai LY; Tiong LL; Bujang AM; Hwang SS; Ong TK; Fong AY Int J Clin Pharm; 2013 Aug; 35(4):621-8. PubMed ID: 23661171 [TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794 [TBL] [Abstract][Full Text] [Related]
17. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858 [TBL] [Abstract][Full Text] [Related]
19. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428 [TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]